Physician profile
Sofya M Rubinchik
NPI 1699706325
$1,292.14
in general payments reported to CMS, 2019-2025
7 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2022: $102 · 2023: $424 · 2024: $229 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $300.87 | 2019-2024 | Austedo Xr, Uzedy |
| Alkermes, INC. | $247.11 | 2022-2025 | Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $228.40 | 2023-2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $206.19 | 2019-2025 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $121.77 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $121.36 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $66.44 | 2023-2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofya Rubinchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.